Using advanced imaging techniques to screen for melanoma
Imaging Modalities for Melanoma Screening and Diagnosis
This study is testing three new imaging methods to see if they can help people with suspicious moles get better and faster screenings for melanoma instead of just visiting a dermatologist.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | OHSU Knight Cancer Institute Academic / other |
| Locations | 1 site (Portland, Oregon) |
| Trial ID | NCT03699995 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the effectiveness of three imaging methods—MoleMapper, Visiomed, and confocal microscopy—in screening for melanoma. Participants will have images of suspicious moles taken using these portable systems, which may provide a reliable alternative to traditional dermatologist visits. The study aims to assess how these imaging techniques can improve the classification of skin lesions and enhance virtual patient triage. Following imaging, participants will undergo a biopsy of any lesions deemed suspicious.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18-80 who have been informed by a provider that they have a pigmented lesion requiring biopsy.
Not a fit: Patients with no suspicious moles or those not participating in the designated skin cancer screening events may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accessible and efficient melanoma screening methods for patients.
How similar studies have performed: Other studies have shown promise in using teledermatology and advanced imaging techniques for skin cancer detection, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Persons who participate in the free skin cancer screening at the PDX Skincare Festival at Oregon Health \& Science University (OHSU) in 2021/2022 (date pending) and are informed by a provider that they have a pigmented lesion for which a biopsy is recommended are potentially eligible to participate in this study. * Persons who participate in the free skin cancer screening at the War on Skin Cancer event at OHSU in 2021/2022 (date pending) or other dates and locations and are informed by a provider that they have a clinically benign or atypical nevi are eligible to participate in the imaging portion of this study. No biopsy will be offered to these participants. * Persons age 18-80 are eligible for the study * Persons of any sex can be enrolled. * Persons of any race are eligible but we anticipate that most participants will be Non-Hispanic whites due to the prevalence of melanoma and other skin cancers in this group. * Only persons who can provide signed statement of informed consent will be enrolled. * Persons who are identified in OHSU Dermatology clinics or through OHSU e-visit and e-consult platforms as having a skin lesion in need of a biopsy for skin cancer * Persons identified via the Melanoma Community Registry (MCR) (IRB approved: 00010561) Exclusion Criteria: * Allergy to the anesthetic (lidocaine).
Where this trial is running
Portland, Oregon
- Sancy Leachman — Portland, Oregon, United States (Recruiting)
Study contacts
- Principal investigator: Joanna Ludzik, MD — OHSU Knight Cancer Institute
- Study coordinator: Sancy Leachman, MD, PhD
- Email: leachmas@ohsu.edu
- Phone: 503-494-4713
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.